|
|
|
 ACH
806
In
Vitro Studies Suggest Promising Outcomes with New HCV
Protease Inhibitor ACH 806 in Combination
with Interferon, Telaprevir, or NM 107
5/05/07
|
|
Albumin
Interfern
Albumin Interferon (Albuferon) and
HCV Polymerase Inhibitor PSI-7851 Advance in Clinical
Trials
7/03/09
Review
Finds Albumin Interferon
for Chronic Hepatitis C Is Effective and Well-tolerated;
Phase 3 Results Show Non-inferiority to Pegylated Interferon
3/20/09
New
Hepatitis C Treatment Trials: HCV Polymerase Inhibitor
R7128, Nucleotide Prodrug IDX184, and
Albumin Interferon (Albuferon)
1/20/09
Albumin Interferon (Albuferon) Administered
Once Every 2-4 Weeks May Be As Effective as Once-weekly
Pegylated Interferon
9/23/08
Safety
and Activity of Once-Monthly
Albinterferon Alfa-2b (Albuferon) in Genotype
2/3 Chronic Hepatitis C Patients
5/23/08
Antiviral
Activity, Pharmacodynamics, and Quality of Life in Genotype
1 Hepatitis C Patients Treated with Albinterferon
(Albuferon)
5/23/08
Albuferon
Dose in Ongoing Trials is Lowered Due to Safety Concerns
1/25/08
|
|
ANA773
and ANA598
First
Participants Treated in Phase 2 Trial of Anadys HCV
Polymerase Inhibitor ANA598
9/15/09
Experimental Interferon-inducer ANA773 Demonstrates
Antiviral Activity In Hepatitis C Treatment Trial
8/21/09
Data
on Experimental Anti-HCV Drugs ITMN-191/R7227, VCH-916,
VCH-222, TMC435, ANA598,
MK-7009, GS-9450, Abbott/Enanta and Idenix Agents
5/12/09
|
BI
201335
Experimental
HCV Protease Inhibitor BI 201335
Demonstrates Promising Results in Combination with Pegylated
Interferon and Ribavirin
11/06/09
SILEN-C1:
Early Antiviral Activity and Safety of BI
201335 Combined with Peginterferon alfa-2a
and Ribavirin in Treatment-naïve Patients with Chronic
Genotype 1 HCV infection
11/06/09
Virological
response and safety of BI 201335
protease inhibitor, peginterferon alfa 2a and ribavirin
treatment of HCV genotype-1 patients with compensated
liver cirrhosis and non-response to previous peginterferon/ribavirin
11/06/09
Investigational
HCV Protease Inhibitor BI 201335
Exhibits Promising Antiviral Activity
11/11/08
Safety and antiviral activity of BI 201335, a new HCV NS3 protease
inhibitor, in treatment-naïve patients with chronic hepatitis
C genotype 1 infection given as monotherapy and in combination
with peginterferon alfa-2a (P) and ribavirin (R)
11/05/08
Safety and antiviral activity of BI 201335, a new HCV NS3 protease
inhibitor, in combination therapy with peginterferon alfa-2a
(P) and ribavirin (R) for 28 days in P+R treatment-experienced
patients with chronic hepatitis C genotype 1 infection
11/05/08 |
Boceprevir
(aka SCH 503034)
SPRINT-1
Study Shows Benefits of Response-guided Therapy with Experimental
HCV Protease Inhibitor Boceprevir
11/06/09
Response-Guided
Therapy for Boceprevir Combination
Treatment? Results from HCV SPRINT-1
11/03/09
Schering-Plough
Completes Enrollment of Phase 3 Trials of Boceprevir
for Chronic Hepatitis C
6/26/09
Experimental
HCV Protease Inhibitor SCH 900518,
with or without Pegylated Interferon, Appears Safe and
Exhibits Good Antiviral Activity
5/01/09
Adding
Boceprevir to PegIntron/Ribavirin
Significantly Improves Sustained Virological Response
in Chronic Hepatitis C Patients
5/01/09
SAFETY
AND ANTIVIRAL ACTIVITY OF SCH
900518 ADMINISTERED AS MONOTHERAPY AND IN COMBINATION
WITH PEGINTERFERON ALFA-2B TO NAIVE AND TREATMENT-EXPERIENCED
HCV-1 INFECTED PATIENTS
5/01/09
HCV
SPRINT-1 Final Results SVR 24 Boceprevir*
plus PegIFN alfa-2b/Ribavirin HCV 1 Treatment
Naïve Patients
5/01/09
Preclinical Characterization of SCH 900518, A Novel Mechanism-Based
Inhibitor of HCV NS3 Protease
4/24/09
A Regional Gastrointestinal Absorption Study
of the HCV NS3 Protease Inhibitor SCH 900518 in Healthy Volunteers
4/24/09
SPRINT-1 Study Design- Boceprevir
4/24/09
SPRINT-2 Design (Naïve Study) - Boceprevir
4/24/09
SCH 900518 Tablet Study Diagram (Phase 2)
- Boceprevir
4/24/09
RESPOND-2 Study Design (Treatment Failure
Trial) - Boceprevir
4/24/09
Schering-Plough Completes
Enrollment of Phase 3 Trial of HCV Protease Inhibitor
Boceprevir
1/30/09
HCV
Protease Inhibitor Boceprevir
plus Pegylated Interferon/Ribavirin Increases Sustained
Virological Response Rate: SPRINT-1 Study
11/04/08
74
Percent of Genotype 1 HCV Patients in Experimental HCV PI Boceprevir Phase
II Study Achieve Sustained Virologic Response (SVR) at
48 Weeks
8/05/08
Schering
Plough Initiates Phase 3 Studies with Experimental Oral
HCV Protease Inhibitor Boceprevir
in Treatment-naive HCV Patients and in Those Who Failed
Prior Treatment
5/23/08
Boceprevir
(NS3 Protease Inhibitor) Combination Therapy
in Non Responders: Phase II Dose Finding Study
4/29/08
Interim Results
from HCV SPRINT-1: RVR/EVR from Phase 2 Study of Boceprevir
Plus Peginterferon alfa-2b/Ribavirin in Treatment-Naïve
Subjects with Genotype-1 CHC -
4/29/08
Boceprevir Added to Pegylated Interferon/Ribavirin
Increases Sustained Response in Treatment-naive Patients
and Some Prior Non-responders
4/29/08 |
GS
9132 and GS 9190
and GS 9450
Data
on Experimental Anti-HCV Drugs ITMN-191/R7227, VCH-916,
VCH-222, TMC435, ANA598, MK-7009, GS-9450,
Abbott/Enanta and Idenix Agents
5/12/09
Safety,
Tolerability, and Pharmacokinetics of GS-9450
in Healthy Male and Female Volunteers
4/24/09
Experimental
HCV Polymerase Inhibitor GS
9190 Shows
Promising Antiviral Activity but Possible Cardiac Side
Effects in Phase 1 Study
12/11/07
Despite
Promising Early Data, Companies Discontinue Experimental
HCV Protease Inhibitor GS 9132
2/13/07 |
|
HCV-796
(HCV Polymerase Inhibitor)
Naturally
Occurring Resistance to HCV Protease
and Polymerase Inhibitors in Treatment-naive
Hepatitis C Patients
1/09/09
Natural
Prevalence of Resistance to HCV
Protease Inhibitors
9/25/08
ViroPharma
and Wyeth Halt Development of HCV-796
for Hepatitis C
4/24/08
Novel
HCV Polymerase Inhibitor VCH-759 Monotherapy
Demonstrates Promising Antiviral Activity
12/07/07
Experimental
Polymerase Inhibitor
HCV-796 is
Safe and Effective in Combination with PegIntron or
Pegasys
12/07/07
|
|
VCH-759, VCH-916, VCH-222
Data
on Experimental Anti-HCV Drugs ITMN-191/R7227, VCH-916,
VCH-222, TMC435,
ANA598, MK-7009, GS-9450, Abbott/Enanta and Idenix Agents
5/12/09
Vertex
Acquires VCH-222 and VCH-759,
Two Experimental Oral HCV Polymerase Inhibitors
3/15/09
Naturally
Occurring Resistance to HCV Protease
and Polymerase Inhibitors in Treatment-naive
Hepatitis C Patients
1/09/09
Natural
Prevalence of Resistance to HCV
Protease Inhibitors
9/25/08
Novel
HCV
Polymerase Inhibitor VCH-759 Monotherapy
Demonstrates Promising Antiviral Activity
12/07/07
|
IDX136,
IDX316, IDX375 and IDX184
IDX184,
A Liver-Targeted Nucleotide HCV Polymerase Inhibitor:
Results of a First-in-Man Safety and Pharmacokinetic Study
5/01/09
Antiviral Activity of the Liver-Targeted
Nucleotide HCV Polymerase Inhibitor IDX184
Correlates with Trough Serum Levels of the Nucleoside
Metabolite in HCV-infected Chimpanzees
5/01/09
Preclinical
Pharmacokinetic and Safety Profile of IDX375,
A Novel and Potent Non-Nucleoside HCV Polymerase Inhibitor
4/24/09
Preclinical
Profiles of IDX136 and IDX316, Two Novel
Macrocyclic HCV Protease Inhibitors
4/24/09 |
IMO-2125
Idera
Pharmaceuticals Begins Phase 1 Trial of Toll-like Receptor
Agonist IMO-2125 for
Chronic Hepatitis C
10/13/09 |
ITMN-191
/ R7227
Oral
HCV Polymerase Inhibitor RG7128 plus Protease Inhibitor
RG7227 (ITMN-191)
Suppresses HCV Viral Load without Interferon or Ribavirin
11/13/09
InterMune and Roche
Begins Trial of Ritonavir-boosted ITMN-191
(RG7227) for Genotype 1 Chronic Hepatitis C Patients
10/06/09
Roche and InterMune Begin
Phase 2b Trial of HCV Protease
Inhibitor RG7227/ITMN-191
9/04/09
Data
on Experimental Anti-HCV Drugs ITMN-191/R7227,
VCH-916, VCH-222, TMC435, ANA598, MK-7009, GS-9450, Abbott/Enanta
and Idenix Agents
5/12/09
Natural
Prevalence of Resistance to HCV
Protease Inhibitors
9/25/08
InterMune
and Anadys Begin Phase 1 Clinical Trials of Experimental
HCV Therapies ITMN-191 and
ANA598
6/06/08
InterMune
Presents Top-line Results from Phase 1b Trial of HCV Protease
Inhibitor ITMN-191
Monotherap
4/04/08
InterMune
Announces Progress on HCV
Protease Inhibitor ITMN-191
1/11/08 |
MK-06080
/ MK-7009
Data
on Experimental Anti-HCV Drugs ITMN-191/R7227, VCH-916,
VCH-222, TMC435, ANA598, MK-7009,
GS-9450, Abbott/Enanta and Idenix Agents
5/12/09
MK-7009
Significantly Improves Rapid Viral Response (RVR) in Combination
with Pegylated Interferon Alfa-2a and Ribavirin in Patients
with Chronic Hepatitis C (CHC) Genotype 1 Infection
4/24/09
Experimental
Nucleoside Inhibitor MK-0608
Suppresses HCV Replication in Chimpanzees
9/29/06 |
Narlaprevir
Boosted
Narlaprevir plus
Pegylated Interferon and Ribavirin Leads to Rapid Viral
Suppression in Genotype 1 Hepatitis C Patients
11/10/09
|
Nitazoxanide
Nitazoxanide
plus Pegylated Interferon and Ribavirin Produces Virological
Response in Some Prior Non-responders with Cirrhosis
11/10/09
Nitazoxanide
Enhances Anti-HCV Activity of Pegylated interferon/ribavirin
and STAT-C Agents
12/08/08
Nitazoxanide
Added to Standard Therapy Improves Response in Patients
with Genotype 4 HCV: STEALTH-C1 Study
5/08/08
Romark
Initiates Phase II Clinical Trial of Nitazoxanide
(Alinia) for Chronic Hepatitis C
8/28/07
|
Pegylated
Interferon Lambda
Pegylated
Interferon Lambda Demonstrates Good Antiviral
Activity, May Cause Fewer Side Effects than Interferon
Alfa
11/03/09
ZymoGenetics
Begins Clinical Trial of Pegylated
Interferon Lambda
2/02/07
|
PSI-879
and PSI-7851
Pharmasset
Selects Investigational HCV Polymerase Inhibitor PSI-879
for Preclinical Development
10/09/09
Pharmasset
Initiates First Clinical Trial of Second-generation HCV
Polymerase Inhibitor PSI-7851
4/10/09 |
R-1626,
RG7128
Oral
HCV Polymerase Inhibitor RG7128
plus Protease Inhibitor RG7227 (ITMN-191) Suppresses HCV
Viral Load without Interferon or Ribavirin
11/13/09
New
Hepatitis C Treatment Trials: HCV Polymerase Inhibitor
R7128, Nucleotide
Prodrug IDX184, and Albumin Interferon (Albuferon)
1/20/09
HCV Polymerase Inhibitor R7128 Demonstrates
Good Antiviral Activity in Genotype 2 or 3 Prior Non-responders
and Relapsers
11/14/08
R7128 plus ITMN-191 Perform Well in
Laboratory Study; STAT-C Combination Clinical Trial Now
Underway
11/14/08
Combination
Therapy with Investigational HCV
Polymerase Inhibitor R7128 Produces Rapid Response
in Patients with Genotype 2/3 HCV
9/12/08
Pharmasset
Releases Preliminary Data from Phase 1 Study of Investigational
HCV Polymerase Inhibitor R7128
8/08/08
R7128 Demonstrates Potent Anti-HCV
Activity in Combination with Pegylated
Interferon/Ribavirin; Ongoing Trial to be Expanded
4/29/08
HCV Polymerase Inhibitor R1626 Produces
Good Response with Pegylated Interferon/Ribavirin and
Has High Barrier to Resistance
4/29/08
Pharmasset
Announces Promising 4-Week Data on Combination Therapy
with
HCV Polymerase Inhibitor R7128
1/11/08
|
STAT-C
Agents
Antiviral
Agents with Activity against Both HIV and Hepatitis C
Virus
6/02/09
Vertex
Acquires VCH-222 and VCH-759,
Two Experimental Oral HCV Polymerase Inhibitors
3/09/09
Companies Announce Phase
1b Study Data for Experimental HCV Polymerase Inhibitor
ANA598 and Cyclophilin
Inhibitor SCY635
1/23/09
Naturally
Occurring Resistance to HCV Protease and Polymerase Inhibitors
in Treatment-naive Hepatitis C Patients
1/03/09
Three
New STAT-C Agents
Show Promise in Preclinical Studies and Early Clinical
Trials: MK-7009, ANA598, and IDX375
11/25/08
R7128
plus ITMN-191 Perform Well in Laboratory Study; STAT-C
Combination Clinical Trial Now Underway
11/14/08
Several
“STAT-C” Agents Discussed
at the Liver Meeting
11/07/08 |
Viramidine
(Taribavirin)
Prodrug Taribavirin Produces Equivalent
Response, but Less Anemia than Ribavirin at 48 Weeks
12/02/08
Taribavirin Efficacy Similar to Ribavirin
in Combination Therapy for Hepatitis C, but with Less
Anemia
5/09/08
Valeant
Reports Promising 12-week Phase IIb Data on Taribavirin
4/01/08
Virological
Response and Safety Outcomes in Chronic Hepatitis C Patients
Treated with Pegylated Interferon plus
Taribavirin (Viramidine)
8/10/07
|
|
TMC435350
Data
on Experimental Anti-HCV Drugs ITMN-191/R7227, VCH-916,
VCH-222, TMC435,
ANA598, MK-7009, GS-9450, Abbott/Enanta and Idenix Agents
5/12/09
OPERA-1 trial (Study TMC435-C201): interim
analysis of safety and antiviral activity of TMC435
in treatment-naïve genotype-1 HCV patients
5/01/09
Antiviral activity and safety of TMC435 combined with peginterferon -2a and ribavirin
in patients with genotype-1 hepatitis C infection who
failed previous IFN-based therapy
5/01/09
Experimental
HCV Protease Inhibitor TMC435350
Demonstrates Favorable Safety and Efficacy
in Phase 2a Trial
11/11/08
Experimental
HCV Protease Inhibitor TMC435350
Demonstrates Promising Activity and Tolerability in
Early Clinical Trial
5/13/08
|
Telaprevir
(aka VX-950)
monotherapy / combination
HCV Protease
Inhibitor Telaprevir
Demonstrates Good Efficacy in Both Treatment-experienced
and Treatment-naive Patients
11/10/09
Vertex
Aims to Receive $250 Million in Milestone Payments for
Anti-HCV Drug Telaprevir
after Approval in Europe
7/14/09
Adding
Telaprevir Improves
Sustained Response to Pegylated Interferon plus Ribavirin
in Genotype 1 Chronic Hepatitis C Patients (PROVE3)
5/01/09
HCV
Protease Inhibitor Telaprevir (VX-950)
Continues to Perform Well in PROVE Trials
11/11/08
Tibotec
Begins Enrolling Phase III Study of HCV
Protease Inhibitor Telaprevir for Hepatitis
C Patients with Prior Treatment Failure
10/24/08
Vertex
Reports Encouraging Data from PROVE3 Trial of HCV Protease
Inhibitor
Telaprevir (VX-950)
6/13/08
Telaprevir plus Pegylated Interferon
and Ribavirin Allows Shorter Therapy for Patients with
Genotype 1 HCV
4/26/08
Vertex
to Start Phase 3 Trials of HCV Protease Inhibitor Telaprevir
(VX-950)
2/01/08
Telaprevir
plus
Pegylated Interferon Is Effective against Both Wild-type
and Drug-resistant HCV Strains
8/17/07
Mutations
That Confer Resistance to HCV Protease Inhibitors
5/01/07
Telaprevir-based
Therapy for HCV May Shorten Treatment Duration from
48 to 24 Weeks for Some Genotype 1 Patients
4/17/07
In
Vitro Studies Suggest Promising Outcomes with New HCV
Protease Inhibitor ACH 806 in Combination with Interferon,
Telaprevir, or NM
107
4/05/07
Telaprevir
Demonstrates Safety and Anti-HCV Activity in 12-week
Interim Analysis
1/05/07 |
|
|
|
|
